| Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. | leukemia, |
| AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. | neuroblastoma,liver,thymoma, |
| Blast crisis accompanied with occurrence of the point-mutational activation of N-ras proto-oncogene and the chromosomal abnormality inv(3q) in chronic myelogenous leukemia presenting thrombocytosis. | leukemia, |
| study reports 2 patients with somatic mosaicism for oncogenic NRAS mutations (G12D and G12S) associated with the development of juvenile myelomonocytic leukemia | leukemia, |
| identified a single activating mutation in NRAS and complete absence of oncogenic mutations in all other genes tested in aggressive pediatric rhabdoid tumors | pediatric, |
| Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes | skin, |
| Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. | skin, |
| Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. | sarcoma, |
| NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfbeta-SMMHC via activation of MEK/ERK axis. | leukemia, |
| Mutations of N-ras oncogene in myelodysplastic syndromes and leukemias detected by polymerase chain reaction. | leukemia, |
| Loss of keratinocytic RXRalpha combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment. | skin, |
| a crucial role of RXRa in suppression of UVB-induced melanomas in the context of driver mutations such as activated CDK4(R24C/R24C) or oncogenic NRAS(Q61K) and altered expression of p53 and PTEN | skin, |
| NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. | leukemia, |
| Our findings suggest that NRAS is an oncogenic driver in serous ovarian tumors. | ovarian, |
| Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. | neoplasm,brain, |
| Transformed NIH 3T3 cells expressing human melanoma N-ras oncogene metastasize to lymph node in nude mice. | skin, |
| Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias. | leukemia, |
| Sodium butyrate suppresses the transforming activity of an activated N-ras oncogene in human colon carcinoma cells. | colorectal, |
| NRAS was identified as a direct target of let-7e and promoted oncogenesis in glioma stem cells. | glioma, |
| Rare mutations in KRAS, NRAS, and BRAF oncogenes have been found in patients with melanoma and colorectal neoplasms. | skin,colorectal,neoplasm, |